Erschienen in:
01.12.2010 | Special Article
Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition
verfasst von:
Satoru Nagase, Hidetaka Katabuchi, Masamichi Hiura, Noriaki Sakuragi, Yoichi Aoki, Junzo Kigawa, Tsuyoshi Saito, Toru Hachisuga, Kiyoshi Ito, Takashi Uno, Noriyuki Katsumata, Shinichi Komiyama, Nobuyuki Susumu, Makoto Emoto, Hiroaki Kobayashi, Hirohito Metoki, Ikuo Konishi, Kazunori Ochiai, Mikio Mikami, Toru Sugiyama, Makio Mukai, Satoru Sagae, Hiroshi Hoshiai, Daisuke Aoki, Masahide Ohmichi, Hiroyuki Yoshikawa, Tsuyoshi Iwasaka, Yasuhiro Udagawa, Nobuo Yaegashi
Erschienen in:
International Journal of Clinical Oncology
|
Ausgabe 6/2010
Einloggen, um Zugang zu erhalten
Abstract
Endometrial carcinoma is one of the most common gynecologic malignancies in Japan and its incidence has increased recently. Although surgery is the cornerstone of the management of patients with endometrial cancer, there is significant variation in Japan with regard to the type of hysterectomy employed. Additionally, it remains controversial whether full nodal staging is required in all patients. Furthermore, adjuvant therapy differs between Japan and Western countries. To delineate clearly the standard of care for endometrial cancer treatment in Japan, the guidelines for the treatment of endometrial cancer were published in 2006 and revised in 2009. The 2009 edition included topics not addressed in the previous edition including the treatment of mesenchymal tumors, for example leiomyosarcoma, and sections covering the treatment of serous and clear-cell adenocarcinoma. These guidelines are composed of nine chapters and include nine algorithms. The guidelines also contain fifty-one clinical questions (CQs) and each CQ consists of recommendations, background, explanations, and references. The treatment recommendations herein are tailored to reflect current Japanese clinical practice and ensure equitable care for all Japanese women diagnosed with endometrial cancer.